- Home
- FLNT vs BTAI Comparison
FLNT vs BTAI Comparison
Compare FLNT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNT | BTAI |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FLNT | BTAI |
|---|---|---|
| Price | $2.07 | $2.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $32.80 |
| AVG Volume (30 Days) | 18.0K | ★ 661.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $212,352,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.56 | $416.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $1.17 |
| 52 Week High | $3.12 | $9.26 |
Technical Indicators
Market Signals| Indicator | FLNT | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 56.86 |
| Support Level | $1.72 | $1.82 |
| Resistance Level | $1.93 | $2.33 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 100.00 | 83.48 |
Price Performance
Historical ComparisonAbout FLNT Fluent Inc.
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.